After third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 net loss in Q2

Following another CEO transition and company restructuring, vTv Therapeutics Inc., the High Point clinical-stage pharmaceutical company, reported a net loss of $3.2 million during the second quarter of 2022.